ASX - By Stock
|
PER |
Re:
US deal for ATL1102
|
|
moll76
|
202 |
74K |
4 |
28/03/21 |
28/03/21 |
ASX - By Stock
|
202
|
74K
|
4
|
|
Charts
|
PER |
Re:
Chart
|
|
moll76
|
5.9K |
2.3M |
10 |
24/03/21 |
24/03/21 |
Charts
|
5.9K
|
2.3M
|
10
|
|
ASX - By Stock
|
PER |
Re:
Ann: Antisense Therapeutics appoints new Non-Executive Director
|
|
moll76
|
37 |
13K |
7 |
23/03/21 |
23/03/21 |
ASX - By Stock
|
37
|
13K
|
7
|
|
Charts
|
PER |
Re:
Chart
|
|
moll76
|
5.9K |
2.3M |
7 |
22/03/21 |
22/03/21 |
Charts
|
5.9K
|
2.3M
|
7
|
|
Charts
|
PER |
Re:
Chart
|
|
moll76
|
5.9K |
2.3M |
7 |
21/03/21 |
21/03/21 |
Charts
|
5.9K
|
2.3M
|
7
|
|
Charts
|
PER |
Re:
Chart
|
|
moll76
|
5.9K |
2.3M |
4 |
21/03/21 |
21/03/21 |
Charts
|
5.9K
|
2.3M
|
4
|
|
Charts
|
PER |
Re:
Chart
|
|
moll76
|
5.9K |
2.3M |
0 |
21/03/21 |
21/03/21 |
Charts
|
5.9K
|
2.3M
|
0
|
|
Charts
|
PER |
Re:
Chart
|
|
moll76
|
5.9K |
2.3M |
11 |
21/03/21 |
21/03/21 |
Charts
|
5.9K
|
2.3M
|
11
|
|
Charts
|
PER |
Re:
Chart
|
|
moll76
|
5.9K |
2.3M |
0 |
20/03/21 |
20/03/21 |
Charts
|
5.9K
|
2.3M
|
0
|
|
Charts
|
PER |
Re:
Chart
|
|
moll76
|
5.9K |
2.3M |
6 |
18/03/21 |
18/03/21 |
Charts
|
5.9K
|
2.3M
|
6
|
|
Charts
|
PER |
Re:
Chart
|
|
moll76
|
5.9K |
2.3M |
3 |
17/03/21 |
17/03/21 |
Charts
|
5.9K
|
2.3M
|
3
|
|
Charts
|
PER |
Re:
Chart
|
|
moll76
|
5.9K |
2.3M |
9 |
17/03/21 |
17/03/21 |
Charts
|
5.9K
|
2.3M
|
9
|
|
Charts
|
PER |
Re:
Chart
|
|
moll76
|
5.9K |
2.3M |
22 |
16/03/21 |
16/03/21 |
Charts
|
5.9K
|
2.3M
|
22
|
|
Charts
|
PER |
Re:
Chart
|
|
moll76
|
5.9K |
2.3M |
3 |
14/03/21 |
14/03/21 |
Charts
|
5.9K
|
2.3M
|
3
|
|
Charts
|
PER |
Re:
Chart
|
|
moll76
|
5.9K |
2.3M |
3 |
14/03/21 |
14/03/21 |
Charts
|
5.9K
|
2.3M
|
3
|
|
Charts
|
PER |
Re:
Chart
|
|
moll76
|
5.9K |
2.3M |
5 |
14/03/21 |
14/03/21 |
Charts
|
5.9K
|
2.3M
|
5
|
|
Charts
|
PER |
Re:
Chart
|
|
moll76
|
5.9K |
2.3M |
7 |
14/03/21 |
14/03/21 |
Charts
|
5.9K
|
2.3M
|
7
|
|
Charts
|
PER |
Re:
Chart
|
|
moll76
|
5.9K |
2.3M |
0 |
14/03/21 |
14/03/21 |
Charts
|
5.9K
|
2.3M
|
0
|
|
ASX - By Stock
|
PER |
Re:
ATL1102 US Patent - very interesting
|
|
moll76
|
44 |
10K |
0 |
13/03/21 |
13/03/21 |
ASX - By Stock
|
44
|
10K
|
0
|
|
Charts
|
PER |
Re:
Chart
|
|
moll76
|
5.9K |
2.3M |
0 |
13/03/21 |
13/03/21 |
Charts
|
5.9K
|
2.3M
|
0
|
|
ASX - By Stock
|
PER |
Re:
ATL1102 US Patent - very interesting
|
|
moll76
|
44 |
10K |
5 |
13/03/21 |
13/03/21 |
ASX - By Stock
|
44
|
10K
|
5
|
|
Charts
|
PER |
Re:
Chart
|
|
moll76
|
5.9K |
2.3M |
5 |
12/03/21 |
12/03/21 |
Charts
|
5.9K
|
2.3M
|
5
|
|
Charts
|
PER |
Re:
Chart
|
|
moll76
|
5.9K |
2.3M |
19 |
07/03/21 |
07/03/21 |
Charts
|
5.9K
|
2.3M
|
19
|
|
Charts
|
PER |
Re:
Chart
|
|
moll76
|
5.9K |
2.3M |
4 |
07/03/21 |
07/03/21 |
Charts
|
5.9K
|
2.3M
|
4
|
|
ASX - By Stock
|
PER |
Re:
Ann: FDA Rare Disease Day 2021
|
|
moll76
|
31 |
13K |
4 |
06/03/21 |
06/03/21 |
ASX - By Stock
|
31
|
13K
|
4
|
|
Charts
|
PER |
Re:
Chart
|
|
moll76
|
5.9K |
2.3M |
2 |
06/03/21 |
06/03/21 |
Charts
|
5.9K
|
2.3M
|
2
|
|
Charts
|
PER |
Re:
Chart
|
|
moll76
|
5.9K |
2.3M |
3 |
06/03/21 |
06/03/21 |
Charts
|
5.9K
|
2.3M
|
3
|
|
Charts
|
PER |
Re:
Chart
|
|
moll76
|
5.9K |
2.3M |
5 |
05/03/21 |
05/03/21 |
Charts
|
5.9K
|
2.3M
|
5
|
|
Charts
|
PER |
Re:
Chart
|
|
moll76
|
5.9K |
2.3M |
2 |
05/03/21 |
05/03/21 |
Charts
|
5.9K
|
2.3M
|
2
|
|
Charts
|
PER |
Re:
Chart
|
|
moll76
|
5.9K |
2.3M |
1 |
05/03/21 |
05/03/21 |
Charts
|
5.9K
|
2.3M
|
1
|
|
ASX - By Stock
|
PER |
Re:
Ann: FDA Rare Disease Day 2021
|
|
moll76
|
31 |
13K |
17 |
04/03/21 |
04/03/21 |
ASX - By Stock
|
31
|
13K
|
17
|
|
Charts
|
PER |
Re:
Chart
|
|
moll76
|
5.9K |
2.3M |
7 |
03/03/21 |
03/03/21 |
Charts
|
5.9K
|
2.3M
|
7
|
|
Charts
|
PER |
Re:
Chart
|
|
moll76
|
5.9K |
2.3M |
7 |
03/03/21 |
03/03/21 |
Charts
|
5.9K
|
2.3M
|
7
|
|
ASX - By Stock
|
PER |
Re:
Sarepta gene therapy study missed key target in Duchennes
|
|
moll76
|
413 |
166K |
11 |
27/02/21 |
27/02/21 |
ASX - By Stock
|
413
|
166K
|
11
|
|
ASX - By Stock
|
PER |
Re:
Sarepta gene therapy study missed key target in Duchennes
|
|
moll76
|
413 |
166K |
3 |
27/02/21 |
27/02/21 |
ASX - By Stock
|
413
|
166K
|
3
|
|
ASX - By Stock
|
PER |
Re:
Ann: ATL1102 DMD Paediatric Investigation Plan submitted to EMA
|
|
moll76
|
47 |
15K |
7 |
27/02/21 |
27/02/21 |
ASX - By Stock
|
47
|
15K
|
7
|
|
ASX - By Stock
|
PER |
Re:
Sarepta gene therapy study missed key target in Duchennes
|
|
moll76
|
413 |
166K |
8 |
27/02/21 |
27/02/21 |
ASX - By Stock
|
413
|
166K
|
8
|
|
ASX - By Stock
|
PER |
Re:
Ann: ATL1102 DMD Paediatric Investigation Plan submitted to EMA
|
|
moll76
|
47 |
15K |
4 |
26/02/21 |
26/02/21 |
ASX - By Stock
|
47
|
15K
|
4
|
|
Charts
|
PER |
Re:
Chart
|
|
moll76
|
5.9K |
2.3M |
5 |
26/02/21 |
26/02/21 |
Charts
|
5.9K
|
2.3M
|
5
|
|
ASX - By Stock
|
PER |
Re:
Sarepta gene therapy study missed key target in Duchennes
|
|
moll76
|
413 |
166K |
4 |
24/02/21 |
24/02/21 |
ASX - By Stock
|
413
|
166K
|
4
|
|
Charts
|
PER |
Re:
Chart
|
|
moll76
|
5.9K |
2.3M |
3 |
24/02/21 |
24/02/21 |
Charts
|
5.9K
|
2.3M
|
3
|
|
Charts
|
PER |
Re:
Chart
|
|
moll76
|
5.9K |
2.3M |
4 |
23/02/21 |
23/02/21 |
Charts
|
5.9K
|
2.3M
|
4
|
|
ASX - By Stock
|
PER |
Re:
Sarepta gene therapy study missed key target in Duchennes
|
|
moll76
|
413 |
166K |
5 |
22/02/21 |
22/02/21 |
ASX - By Stock
|
413
|
166K
|
5
|
|
Charts
|
PER |
Re:
Chart
|
|
moll76
|
5.9K |
2.3M |
5 |
20/02/21 |
20/02/21 |
Charts
|
5.9K
|
2.3M
|
5
|
|
Charts
|
PER |
Re:
Chart
|
|
moll76
|
5.9K |
2.3M |
1 |
19/02/21 |
19/02/21 |
Charts
|
5.9K
|
2.3M
|
1
|
|
Charts
|
PER |
Re:
Chart
|
|
moll76
|
5.9K |
2.3M |
3 |
17/02/21 |
17/02/21 |
Charts
|
5.9K
|
2.3M
|
3
|
|
ASX - By Stock
|
PER |
Re:
Ann: ANP meeting with US FDA granted for ATL1102 in DMD
|
|
moll76
|
79 |
24K |
7 |
17/02/21 |
17/02/21 |
ASX - By Stock
|
79
|
24K
|
7
|
|
ASX - By Stock
|
PER |
Re:
Ann: ANP meeting with US FDA granted for ATL1102 in DMD
|
|
moll76
|
79 |
24K |
2 |
16/02/21 |
16/02/21 |
ASX - By Stock
|
79
|
24K
|
2
|
|
ASX - By Stock
|
PER |
Re:
Ann: ANP meeting with US FDA granted for ATL1102 in DMD
|
|
moll76
|
79 |
24K |
2 |
16/02/21 |
16/02/21 |
ASX - By Stock
|
79
|
24K
|
2
|
|
Charts
|
PER |
Re:
Chart
|
|
moll76
|
5.9K |
2.3M |
3 |
15/02/21 |
15/02/21 |
Charts
|
5.9K
|
2.3M
|
3
|
|